Biomaterial Database

[Clinical significance of pharmacogenetics in psychiatry]. 2013

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Zakład Farmakogenetyki, Uniwersytet Medyczny w Łodzi.

One of the problems in the pharmacotherapy of mental disorders is among others a lack of appropriate response to treatment, which may be associated with ineffective therapy, adverse drug reactions and self medication. Participation of cytochrome P-450 isoenzymes (including CYP1A2, CYP2C19, CYP2D6, CYP3A4) in the metabolism of psychotropic drugs contributes to risk of adverse interactions, both in pharmacokinetic and pharmacodynamic phase. Pharmacogenetic studies may have an increasing importance in the field of improving both therapeutic effectiveness and safety of psychotropic drugs in treatment of mental disorders.

UI	MeSH Term	Description	Entries
D010597	Pharmacogenetics	A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).	Pharmacogenomics
D011619	Psychotropic Drugs	A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents).	Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D003577	Cytochrome P-450 Enzyme System	A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism.	Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001523	Mental Disorders	Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders

Related Publications

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Clinical applications of pharmacogenetics in psychiatry.

June 2002, Psychopharmacology,

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

[Clinical significance of pharmacogenetics].

May 1967, Deutsche medizinische Wochenschrift (1946),

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

[The role of pharmacogenetics in clinical psychiatry].

March 2006, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology,

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Pharmacogenetics in Psychiatry.

July 2020, Pharmacopsychiatry,

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Pharmacogenetics in Psychiatry.

January 2018, Advances in pharmacology (San Diego, Calif.),

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Pharmacogenetics in Psychiatry: An Update on Clinical Usability.

January 2020, Frontiers in pharmacology,

Jadwiga Skrętkowicz, and Małgorzata Barańska, and Mariola Rychlik-Sych

Pharmacogenetics in psychiatry: translating research into clinical practice.

July 2012, Molecular psychiatry,